Takeda Pharmaceutical Company Limited (TAK)

Takeda Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	457,800	533,530	849,695	966,222	637,614
Short-Term Investments	15,089	20,174	25,305	36,598	15,822
Cash & Cash Equivalents	472,889	553,704	875,000	1,002,820	653,436
Cash Growth	-14.60%	-36.72%	-12.75%	53.47%	-9.92%
Receivables	668,403	649,429	696,644	783,091	757,005
Inventory	1,209,869	986,457	853,167	753,881	759,599
Other Current Assets	207,419	208,366	168,831	173,101	299,392
Total Current Assets	2,558,580	2,397,956	2,593,642	2,712,893	2,469,432
Property, Plant & Equipment	1,989,777	1,691,229	1,582,800	1,453,917	1,386,370
Long-Term Investments	430,608	378,857	330,133	348,350	369,455
Goodwill and Intangibles	9,684,749	9,060,380	8,226,293	7,943,023	8,183,889
Other Long-Term Assets	445,078	429,328	445,150	454,110	411,948
Total Long-Term Assets	12,550,212	11,559,794	10,584,376	10,199,400	10,351,662
Total Assets	15,108,792	13,957,750	13,178,018	12,912,293	12,821,094
Accounts Payable	547,521	649,233	516,297	343,838	318,816
Current Debt	510,672	525,137	400,064	270,206	682,523
Other Current Liabilities	1,254,910	1,307,570	1,229,369	1,159,132	1,174,559
Total Current Liabilities	2,313,103	2,481,940	2,145,730	1,773,176	2,175,898
Long-Term Debt	5,164,334	4,577,010	4,610,361	5,130,895	4,905,616
Other Long-Term Liabilities	357,351	544,128	738,404	831,045	1,012,094
Total Long-Term Liabilities	5,521,685	5,121,138	5,348,765	5,961,940	5,917,710
Total Liabilities	7,834,788	7,603,078	7,494,495	7,735,116	8,093,608
Total Debt	5,675,006	5,102,147	5,010,425	5,401,101	5,588,139
Debt Growth	11.23%	1.83%	-7.23%	-3.35%	-7.46%
Retained Earnings	1,391,203	1,541,146	1,479,716	1,509,906	1,369,972
Shareholders' Equity	7,273,264	6,354,122	5,683,019	5,173,037	4,723,483
Net Cash / Debt	-5,202,117	-4,548,443	-4,135,425	-4,398,281	-4,934,703
Working Capital	245,477	-83,984	447,912	939,717	293,534
Book Value Per Share	2317.94	2049.24	1817.57	1660.40	1509.09

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).